The Efficiency and Safety of Triple-Drug Combination of Albumin-Bound Paclitaxel, Anlotinib and PD-1/L1 Inhibitors in the 2nd or Above Line of Advanced NSCLC: A Retrospective Cohort Study
Our study displayed that triple-drug combination of nab-ptx, anlotinib and PD-1/L1 inhibitors showed promising efficiency and tolerated cytotoxicity in the 2<sup>nd</sup> or above line treatment of advanced NSCLC, indicating the potential of such regimen as an important option for second-line treatment of advanced NSCLC. However, due to limitations in patient numbers, its actual clinical value awaits further research confirmation.
Authors
- Xiaobing Li (ORCID: https://orcid.org/0000-0002-3332-0575)
- Yuebing Wu
- Jing Tang (ORCID: https://orcid.org/0000-0003-1013-147X)
- De Pei Wu
Institutions
- Hubei Cancer Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Cancer Management and Research
- Published
- 2024-08-01
- DOI
- https://doi.org/10.2147/cmar.s472196
- Citations
- 10
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.83
Funders
- Natural Science Foundation of Hubei Province